Aldeyra Therapeutics (NASDAQ:ALDX) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aldeyra Therapeutics (NASDAQ:ALDX – Get Rating) in a report issued on Friday morning, Benzinga reports. HC Wainwright currently has a $15.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q1 2023 earnings at ($0.30) EPS.

Other equities research analysts have also recently issued reports about the stock. Citigroup raised their price objective on shares of Aldeyra Therapeutics from $23.00 to $28.00 in a research report on Friday. StockNews.com upgraded shares of Aldeyra Therapeutics from a sell rating to a hold rating in a report on Monday, November 14th.

Aldeyra Therapeutics Stock Down 2.2 %

Shares of NASDAQ:ALDX opened at $7.02 on Friday. Aldeyra Therapeutics has a 52-week low of $2.36 and a 52-week high of $8.00. The stock has a market cap of $411.09 million, a P/E ratio of -6.62 and a beta of 1.07. The business has a fifty day moving average of $6.65 and a two-hundred day moving average of $6.17. The company has a quick ratio of 11.78, a current ratio of 11.78 and a debt-to-equity ratio of 0.10.

Hedge Funds Weigh In On Aldeyra Therapeutics

Hedge funds have recently made changes to their positions in the stock. Natixis acquired a new position in Aldeyra Therapeutics during the fourth quarter worth $308,000. Jane Street Group LLC purchased a new position in Aldeyra Therapeutics during the 4th quarter valued at about $440,000. Laidlaw Wealth Management LLC acquired a new position in Aldeyra Therapeutics in the 4th quarter valued at about $125,000. Millennium Management LLC increased its stake in Aldeyra Therapeutics by 31.5% during the fourth quarter. Millennium Management LLC now owns 850,088 shares of the biotechnology company’s stock worth $5,917,000 after purchasing an additional 203,694 shares during the period. Finally, Morgan Stanley lifted its position in shares of Aldeyra Therapeutics by 4.2% during the fourth quarter. Morgan Stanley now owns 315,250 shares of the biotechnology company’s stock worth $2,194,000 after purchasing an additional 12,607 shares in the last quarter. Hedge funds and other institutional investors own 63.11% of the company’s stock.

About Aldeyra Therapeutics

(Get Rating)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.